Pharmaceutical fraud

Short description: Type of criminal activity

The examples and perspective in this article deal primarily with the United States and do not represent a worldwide view of the subject. You may improve this article, discuss the issue on the talk page, or create a new article, as appropriate. (August 2015) (Learn how and when to remove this template message)

|

Pharmaceutical fraud is when pharmaceutical companies engage in illegal, fraudulent activities to the detriment of patients and/or insurers. Examples include counterfeit drugs that do not contain the active ingredient, false claims in packaging and marketing, suppression of negative information regarding the efficacy or safety of the drug, and violating pricing regulations.

## Contents

* 1 Definition
* 2 History
* 3 Types of fraud
* 3.1 GMP violations
* 3.2 Off-label marketing
* 3.3 Best price fraud
* 3.4 Medicaid price reporting
* 3.5 Manufactured compound drugs
* 3.6 Kickbacks
* 4 Examples of fraud cases
* 5 See also
* 6 References
* 7 External links and resources

## Definition

Pharma fraud refers to:

* Trade involving counterfeit drugs: the practice of falsely claiming to be an authorized product of another firm, including but not limited to the use of another firm's mark to deceive the public.[1]
* Deliberately manufacturing and marketing products that do not contain the required active ingredients or not contain the right amount of active ingredient.[2][3]
* Packaging and labeling of drugs that make false claims regarding medical properties, including but not limited to the active medical ingredients, the date of expiration of products, or the methods of storage.[4]
* Marketing of products using false claims regarding the efficacy of the product which will lead to the irrational use[5][6] of medicines or deliberately failing to provide information about safety concerns of the product.
* Deliberate suppression of data, including evidence from clinical trials, that reveal adverse effects of the medicine.[7][8]
* Serious compliance deficiencies with Current Good Manufacturing Practice (CGMP) .[9]
* Overbilling.
* Bait & Switch in which the purchaser receives a cheaper product at the retail level.

## History

Because of a lack of regulation and enforcement, the quality, safety and efficacy of both imported and locally manufactured medicines in many developing countries cannot be guaranteed. Subsequently, smuggling and illegal importation of drugs are common. Substandard and counterfeit drugs are then not only sold in these countries but also exported or re-exported.[10] According to the World Customs Organization, counterfeit drugs are a $200 billion a year industry that kills hundreds of thousands of people annually.[11]

## Types of fraud

Main article: List of largest pharmaceutical settlements in the United States

See also: List of off-label promotion pharmaceutical settlements

In the United States, there are several different schemes[12] used to defraud the health care system which are particular to the pharmaceutical industry.

* Good Manufacturing Practice (GMP) Violations
* Off Label Marketing
* Best Price Fraud
* CME Fraud
* Medicaid Price Reporting
* Manufactured Compound Drugs

### GMP violations

Involve fraud with the Good Manufacturing Practice (GMP) Regulations which require manufacturers to have adequately equipped manufacturing facilities, adequately trained personnel, stringent control over the manufacturing process, appropriate laboratory controls, complete and accurate records, reports, appropriate finished product examination, and so on. Certain violations of the Good Manufacturing Practice Regulations may be the basis for a False Claims Act lawsuit.[13]

### Off-label marketing

See also: Medicine:List of off-label promotion pharmaceutical settlements

Though physicians may prescribe drugs for off-label usage known as off-label marketing, the Food and Drug Administration (FDA) prohibits drug manufacturers from marketing or promoting a drug for a use that the FDA has not approved. A manufacturer illegally "misbrands" a drug if the drug's labeling includes information about its unapproved uses. A drug is deemed misbranded unless its labeling bears adequate directions for use. The courts have agreed with the FDA that the Food, Drug, and Cosmetic Act (FDCA) requires information not only on how a product is to be used (e.g., dosage and administration), but also on all the intended uses of the product. In 2004, whistleblower David Franklin prevailed in a suit under the False Claims Act against Warner-Lambert, resulting in a $430 million settlement in the Franklin v. Parke-Davis case. It was the first off-label promotion case successfully brought under the False Claims Act in U.S. history. Oral statements and materials presented at industry-support scientific and educational activities may provide evidence of a product's intended use. If these statements or materials promote a use that is inconsistent with the product's approved labeling, the product is misbranded under the FDCA for failure to bear labeling with adequate directions for all intended uses.[14]

### Best price fraud

A figure reported by the manufacturer to CMS in quarterly reports under the Medicaid Rebate Program, it is used to calculate the Medicaid reimbursement rate. It is defined as the lowest price available to any wholesaler, retailer, provider, health maintenance organization (HMO), nonprofit entity, or the government. BP excludes prices to the Indian Health Service (IHS), Department of Veterans Affairs (DVA), Department of Defense (DOD), the Public Health Service (PHS), 340B covered entities, Federal Supply Schedule (FSS), state pharmaceutical assistance programs, depot prices, and nominal pricing. BP includes cash discounts and free goods that are contingent upon purchase, volume discounts, and rebates. The fraud occurs as the manufacturer falsely self-reports its Best Price.[15]

### Medicaid price reporting

In order to decrease the amounts owed to states under the Medicaid Drug Rebate Program, some companies misrepresented material facts regarding the regulatory origin/status of their brand name drugs, the AMP, and/or the best price. Despite the Government's good faith reliance to charge manufacturers a unit rebate amount based upon the manufacturer's own representation of drug status, and price, some manufacturers have deceptively and fraudulently, breached their duty to deal honestly with the Government.[16]

### Manufactured compound drugs

FDA guidelines authorize pharmacists to "compound" or mix medications only in response to a physician's valid prescription. This assumes, of course, that the physician intends that the medication be compounded. The regulations further require that the mixed or compounded medications are medically necessary and not commercially available. Illegal compounding includes compounding of ingredients such that the compounded drug is tantamount to commercially available medications, involving mass manufacturing of drugs under the guise of compounding.

Federal law, including the Centers for Medicare and Medicaid Services (CMS) guidelines and the regulations of other Government Healthcare Programs, prohibit coverage of claims for "compounded" medications when the claims are submitted by a company that is mass manufacturing large amounts of unapproved drugs in violation of the Federal Food, Drug and Cosmetic Act (FFDCA), under the guise of "compounding."[17]

### Kickbacks

Kickbacks are rewards such as cash, jewelry, free vacations, corporate sponsored retreats, or other lavish gifts used to entice medical professionals into using specific medical services. This could be a small cash kickback for the use of an MRI when not required, or a lavish doctor/patient retreat that is funded by a pharmaceutical company to entice the prescription and use of a particular drug.[12]

People engaging in this type of fraud are also subject to the federal Anti-Kickback statute.

## Examples of fraud cases

* $3 billion GSK settlement. On 2 July 2012, GlaxoSmithKline pleaded guilty to criminal charges and agreed to a $3 billion settlement of the largest health-care fraud case in the U.S. and the largest payment by a drug company.[18] The settlement is related to the company's illegal promotion of prescription drugs, its failure to report safety data,[19] bribing doctors, and promoting medicines for uses for which they were not licensed. The drugs involved were Paxil, Wellbutrin, Advair, Lamictal, and Zofran for off-label, non-covered uses. Those and the drugs Imitrex, Lotronex, Flovent, and Valtrex were involved in the kickback scheme.[20][21][22] The government investigation of GSK was launched largely on the basis of information provided by four whistleblowers who filed two qui tam (whistleblower) lawsuits against the company under the False Claims Act. GSK settled the whistleblowers' lawsuits for a total of $1.017 billion out of the $3 billion settlement, the largest civil False Claims Act settlement to date.[23]
* Pfizer $2.3 billion settlement: Pfizer settled multiple civil and criminal allegations for $2.3 billion in the largest case of pharmaceutical and health care fraud in US history. The drugs involved were Bextra (an anti-inflammatory drug), Geodon (an anti-psychotic drug), Lipitor (a cholesterol drug), Norvasc (anti-hypertensive drug), Viagra (erectile dysfunction), Zithromax (antibiotic), Zyrtec (antihistamine), Zyvox (an antibiotic), Lyrica (an anti-epileptic drug), Relpax (anti-migraine drug), Celebrex (anti-inflammatory drug), and Depo-provera (birth control).[24]
* Merck $650 million settlement: Merck settled a nominal pricing fraud case in which the company was accused of taking kickbacks and violating Medicaid best price regulations for various drugs.[25][26]
* United States et al., ex rel. Jim Conrad and Constance Conrad v. Forest Pharmaceuticals, Inc, et al. involved a drug manufacturer selling a drug, Levothroid, that had never been approved by the FDA. These allegations settled for $42.5 million due to multiple whistleblowers stepping forward to provide detailed information on the alleged fraud. The collective reward to the relators in this case was over $14.6 million.[27][28]
* In response to a meningitis epidemic in Niger from February to May 1995 (41,000 cases reported), the Niger authorities organized an extensive vaccination campaign. In March 1995, Niger received a donation of 88,000 Pasteur Mérieux and SmithKline Beecham vaccines from neighboring Nigeria. A Médecins Sans Frontières (MSF) team working with local health authorities noticed that the vaccines from Nigeria had an unusual appearance and inquiries were made. Pasteur Mérieux laboratories confirmed that the batch numbers and the expiration dates did not correspond to their manufacturing records. The drugs supplied by these companies had been substituted with counterfeit drugs. Tests carried out found no traces of active product, which confirmed that they were false. Bottles and labels were, however, copied to perfection. According to estimates, around 60,000 persons were inoculated with false vaccines out of a total 5 million vaccinated during the campaign.[29]

## See also

* Big Pharma (2006) by Jacky Law
* Bad Pharma (2012) by Ben Goldacre
* Drug fraud
* Health care fraud
* Lists about the pharmaceutical industry
* 2025 Counterfeit medication scandal

## References

1. ↑ Sixty-First World Health Assembly (7 April 2008), Counterfeit medical products: Report by the Secretariat (A61/16, Provisional agenda item 11.13), World Health Organization, https://www.who.int/gb/ebwha/pdf_files/A61/A61_16-en.pdf , Report by the Secretariat, A61/16, 7 April 2008.
2. ↑ Wellcome Trust (13 February 2008). "Fake Malaria Drugs Made In China: Tracking Down The Threat To Global Health". ScienceDaily. https://www.sciencedaily.com/releases/2008/02/080212085828.htm.
3. ↑ Newton, Paul N; Fernandez, Facundo M; Plançon, Aline; Mildenhall, Dallas C; Green, Michael D; Li, Ziyong; Christophel, Eva Maria; Phanouvong, Souly et al. (12 February 2008). "A Collaborative Epidemiological Investigation into the Criminal Fake Artesunate Trade in South East Asia". PLOS Med (PLOS) 5 (2). doi:10.1371/journal.pmed.0050032. PMID 18271620.
4. ↑ Panosian Dunavan, Claire (9 May 2008). "Drug safety crisis hits home: Facing the tainted heparin threat and other pharmaceutical concerns, patients must speak up — and the government must crack down". The Baltimore Sun. http://www.baltimoresun.com/news/opinion/oped/bal-op.heparin09may09,0,356719.story.
5. ↑ Laing, R.O. (1990). "Rational Drug Use: An Unsolved Problem". Tropical Doctor 20 (3): 101–103. doi:10.1177/004947559002000303. PMID 2219416.
6. ↑ Rational use of medicines: progress in implementing the WHO medicines strategy, Report by the Secretariat (EB118/6, Executive Board, 118th Session), 11 May 2006, https://www.who.int/gb/ebwha/pdf_files/EB118/B118_6-en.pdf
7. ↑ Silverman, Ed (3 July 2005). "2000 study by Merck showed Vioxx risk Results not given to FDA". Star-Ledger.
8. ↑ Mehrbanm, Morse (July–August 1998), "Failure to disclose adverse health consequences of a product constitutes health fraud", NCRHI Newsletter, http://findarticles.com/p/articles/mi_qa3879/is_199807/ai_n8786081
9. ↑ "Pharmaceutical Fraud Lawyer | Pharma Whistleblower | Brown LLC" (in en). https://ifightforyourrights.com/whistleblower-lawyer/pharma-fraud/.
10. ↑ "Substandard and counterfeit medicines (Fact sheet N°275)". Media centre. World Health Organization. November 2003. https://www.who.int/mediacentre/factsheets/2003/fs275/en/.
11. ↑ Irish, John (10 June 2010). "Customs group to fight $200 bln bogus drug industry". Paris, France: Reuters. https://www.reuters.com/article/us-customs-drugs-idUSTRE65961U20100610.
12. ↑ 12.0 12.1 "Financial Crimes to the Public Report 2006". FBI. 2006. https://www.fbi.gov/stats-services/publications/fcs_report2006/financial-crimes-report-to-the-public-fiscal-year-2006#Health.
13. ↑ "The Top 12 GMP Violations". Fierce Pharma Manufacturing. http://www.fiercepharmamanufacturing.com/special-reports/top-12-gmp-violations.
14. ↑ Kesselheim, Aaron S.; Mello, Michelle M.; Studdert, David M. (2011). "Strategies and Practices in Off-Label Marketing of Pharmaceuticals: A Retrospective Analysis of Whistleblower Complaints". PLOS Medicine 8 (4). doi:10.1371/journal.pmed.1000431. PMID 21483716.
15. ↑ "State Medicaid Policies and Oversight Activities Related to 340B Purchased Drugs". HHS-OIG. https://www.scribd.com/doc/57969807/HHS-OIG-Review-of-State-Medicaid-Policies-and-Oversight-Activities-Related-to-340B-Purchased-Drugs.
16. ↑ "Average Manufacturer Price and Average Sales Price Reporting Requirements". HHS-OIG. https://oig.hhs.gov/documents/special-advisory-bulletins/882/SpAdvBulletin_AMP_ASP.pdf.
17. ↑ "PRESCRIPTION DRUGS: State and Federal Oversight of Drug Compounding by Pharmacies". United States General Accounting Office. http://www.pharmwatch.org/comp/gao.pdf.
18. ↑ "GlaxoSmithKline". 4 July 2012. https://www.bbc.co.uk/news/world-us-canada-18673220.
19. ↑ "GlaxoSmithKline Agrees to Pay $3 Billion in U.S. Drug Settlement". Bloomberg.com. 2 July 2012. https://www.bloomberg.com/news/2012-07-02/glaxosmithkline-agrees-to-pay-3-billion-in-u-s-drug-settlement.html.
20. ↑ Fred Mogul (2 July 2012). "NY to Get Millions in GlaxoSmithKlein Settlement". WNYC. http://www.wnyc.org/articles/wnyc-news/2012/jul/02/drug-giant-pays-record-setting-fine/.
21. ↑ "BBC News -GlaxoSmithKline to pay $3bn in US drug fraud scandal". BBC Online. https://www.bbc.co.uk/news/world-us-canada-18673220.
22. ↑ Thomas, Katie; Schmidt, Michael S. (July 2, 2012). "Glaxo Agrees to Pay $3 Billion in Fraud Settlement". The New York Times. https://www.nytimes.com/2012/07/03/business/glaxosmithkline-agrees-to-pay-3-billion-in-fraud-settlement.html.
23. ↑ "P&C's Glaxo whistleblower case accounts for $1.5 billion out of Glaxo's record $3 billion settlement." Phillips & Cohen LLP Press Release. July 2, 2012.
24. ↑ "JUSTICE DEPARTMENT ANNOUNCES LARGEST HEALTH CARE FRAUD SETTLEMENT IN ITS HISTORY". DOJ. 2009-09-02. https://www.justice.gov/usao/ma/news/Pfizer/Pfizer - PR (Final).pdf.
25. ↑ "Huge Percentage of Financial Fraud Against U.S. Government Comes From Healthcare Industry". Deep Harm. 2009-09-02. http://www.dailykos.com/story/2011/06/06/982659/-Huge-Percentage-of-Financial-Fraud-Against-US-Government-Comes-From-Healthcare-Industry.
26. ↑ "Top 20 Cases". Taxpayers Against Fraud. 2011-06-01. http://www.taf.org/top20.htm.
27. ↑ "Forest Whistleblower Cases Settle for Over $300 million". PRWeb. 2010-09-15. http://www.prweb.com/releases/2010/09/prweb4525334.htm.
28. ↑ "Drug Maker Forest Pleads Guilty". Department of Justice. 2010-09-15. https://www.justice.gov/opa/pr/2010/September/10-civ-1028.html.
29. ↑ Pécoul, Bernard (27 January 1999). "Access to Essential Drugs in Poor CountriesA Lost Battle?". JAMA 281 (4): 361. doi:10.1001/jama.281.4.361.

## External links and resources

1. Masterminds Behind Pharmaceutical Fraud Deserve Prison Time
2. Blowing the Whistle on Health Care Fraud
3. Health Care Fraud Prevention

* v
* t
* e

Medical harm

Concepts|

* Iatrogenesis
* Medical malpractice
* Medical error
* Patient safety
* Medical debt
* Unnecessary health care
* Adverse effect
* Patient abuse

Related concerns|

* Adverse drug reaction
* Hospital-acquired pneumonia
* Hospital-acquired infection
* Hand washing

Records and histories|

* Drug pollution (List)

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Pharmaceutical fraud. Read more

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Medicine:Pharmaceutical_fraud&oldid=4017369"
*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template